Key result
Remdesivir can induce bradycardia in COVID-19 via direct cardiomyocyte cytotoxicity, requiring targeted management.
Why the study?
Remdesivir can induce significant cytotoxic effects on cardiac myocytes including bradycardia, but the pathophysiological mechanisms and management strategies are not well understood.
What are the mechanisms, diagnostic, and management strategies for remdesivir-induced bradycardia in COVID-19 patients?
What are the mechanisms, diagnostic, and management strategies for remdesivir-induced bradycardia in COVID-19 patients?
Remdesivir use in COVID-19 patients is associated with bradycardia, necessitating awareness of its pathophysiological mechanisms and management strategies.
May warrant monitoring for bradycardia with remdesivir; leaves open mechanisms and management strategies.
Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because it curbs the viral load expansion. Among patients hospitalized as a result of lower respiratory tract infection, remdesivir proved to improve recovery time; however, remdesivir also can induce significant cytotoxic effects on cardiac myocytes. In this narrative review, we discuss the pathophysiological mechanism of remdesivir-induced bradycardia and diagnostic and management strategies for these patients. We conclude that further research is necessary to understand better the mechanism of bradycardia in coronavirus disease 2019 patients with or without cardiovascular disorder treated with remdesivir.
No takes yet. Share an insight, caveat, or question.
Kanagala et al. (2023) conducted a review in Coronavirus disease 2019. Remdesivir was evaluated. Remdesivir treatment in patients with coronavirus disease 2019 can induce bradycardia through cytotoxic effects on cardiac myocytes, requiring specific diagnostic and management strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: